Panel Discussion: Addressing Concerns Over Cuts to FDA, NIH, CDC & CMS: What it Means for Innovation, Compliance & Talent Retention
Time: 9:30 am
day: Day 1
Details:
- How cuts to agencies like FDA, NIH, CMS, and CDC may delay approvals, complicate drug development, and hinder access to government-supported programs
- How uncertainty fuels tension between legal teams and commercial functions
- Navigate a shifting regulatory environment amid “brain drain,” reassignment, and ambiguity around enforcement priorities at agencies including DOJ
